Third Amendment to Manufacturing and Supply Agreement dated December 1, 2023, by and between the Registrant and Patheon UK Limited

1 The Parties hereby also agree that this Manufacturing and Supply Agreement, and this Amendment thereto, shall not amend or otherwise affect the Manufacturing and Supply Agreement between the Parties dated 4 April 2014, as amended, with respect to the product EXPAREL®, unless otherwise agreed upon in writing by the Parties.

Patheon will charge a monthly Base Fee, as forth below:

For the avoidance of doubt, the Base Fee will accrue under either the Technical Transfer Agreement, or this Agreement, but not both.

If, at Pacira’s election and following the FDA Approval Date, the Manufacturing Suite will not to be used for Manufacture for at least six (6) consecutive months (as applied to the Phase I Filling Space prior to the Phase III Manufacturing Suite Clearance Date, and as applied to both the Phase I Manufacturing Space, if Pacira exercised its Phase I Option pursuant to Section 2.10(b), and the Phase III Manufacturing Suite, after the Phase III Manufacturing Suite Clearance Date), then the Base Fee will be reduced as follows, provided that Pacira gives notice to Patheon of its intention not to use such Manufacturing Suite and Patheon agrees to such non- use (such agreement not to be unreasonably withheld, conditioned or delayed) (the “Agreed Non-Use”):

[**]% discount for the first three (3) months after the later of: (i) Manufacture of the last batch of Product or (ii) the date of Agreed Non-Use;

[**]% discount from the then current Base Fee for each subsequent month after the above 3- Month Period, to be effective until the date that is three (3) months before the resumption of Manufacturing in such Manufacturing Suite.

Should Manufacture at such Manufacturing Suite be subject to an Agreed Non-Use in accordance with the preceding paragraphs, Pacira shall provide not less than three (3) months’ notice if it wishes Patheon to resume Manufacture at such Manufacturing Suite. During such 3- month notice period and thereafter, the [**]% Base Fee discount will not apply, and the Base Fee will be payable for such Manufacturing Suite in accordance with the table in paragraph I of this

Schedule 2.1(a) above. A reduction of the Base Fee as described above shall not affect the amount of any Phase I Filling Space Fee.

An additional fee is, or will be, payable as set forth below in relation to the Phase I Filling Space:

The Phase I Filling Space Fee stated herein is agreed upon by both parties for the 2019 calendar year. The Phase I Filling Space Fee will be adjusted on 1st January of each subsequent calendar year (first review 1st January 2020) to reflect any change in UK Consumer Price Index: All Items Index published by the Office for National Statistics (as published at www.ons.gov.uk, specific details are located at http://www.ons.gov.uk/ons/rel/cpi/consumer-price-indices) during the previous 12 months (based on the average of the monthly changes over the 12-month period).

The Phase I Filling Space Fee is payable in addition to the applicable Base Fee.

[**] bulk batch: [**] vials

[**] bulk batch: [**] vials

[**] bulk development or engineering batch: [**] vials [**] bulk development or engineering batch: [**] vials

The parties’ non-binding expectations are that Pacira will order at least [**] vials of Product per calendar year. At the end of each calendar year (commencing at the end of 2020), if the Annual Volume is less than [**] % of [**] vials (i.e. less than [**] vials), then Patheon may invoice and Pacira will pay Patheon the Product Fee for the shortfall of Product in an amount calculated as follows:

Amount due to Patheon = ([**] vials – Annual Volume) × £ [**]

Examples:

Note: the vial fee in the above examples is shown for illustration only and would be adjusted in accordance with the annual inflation mechanism for the Product Fee.

Any amount payable would be adjusted on a pro rata basis for any calculation period that does not include a full calendar year, e.g. on expiration or termination of this Agreement.

Pacira will not be obliged to pay any amount under this reconciliation process if and to the extent that a shortfall occurs because either (i) Patheon is unable to supply Purchase Orders as a result of delay in the Phase III Timeline (as set out in Exhibit 2.1-E of the Technical Transfer Agreement) that is caused by the acts or omissions of Patheon, (ii) Patheon’s failure to deliver product in accordance with any Purchase Order issued by Pacira consistent with the terms of this Agreement or (iii) Patheon’s inability to accommodate any portion of a Forecast as contemplated in Section 2.3(a). As stated above for the definition of “Annual Volume”, any Late Product will be counted for the purpose of the Annual Volume.

For any development or engineering batches of Product ordered by Pacira the Parties agree as follows:

Product Fees are payable for all other types of batches (commercial or non-commercial, including PLGA batches) as set out in the Product Fee table above, and all vials produced from such batches shall count towards the applicable Annual Volume. For clarity, all batches for which a Product Fee is payable shall count towards the achievement of the Annual Volume.

ii.Cap on Total Cost for Non-Conforming Batch: In the event that a batch produces Non- Conforming Product (other than by reason of a Patheon Nonconformance), the Parties agree that the total amount payable for such Non-Conforming Product batch through (i) Product Fee or (ii) Costs of terminal sterilisation performed by third party and associated shipping costs, in each case (i)-(ii) as determined in accordance with this Agreement shall in no event exceed the total amount that would have been payable in Product Fees for such batch(es) if the production was

only conforming Product as set out in the Product Fee table above and subject to the minimum batch fee.

iii.Shared Operational Efficiencies: The Parties understand and agree that each Party will work in good faith to identify operational efficiencies or other method of cost saving that could be implemented to reduce the overall costs to manufacture Product. Without limiting the foregoing, if either Party identifies any such efficiency or method that would require Pacira to incur additional costs in connection with the implementation of such efficiency or method, then the Parties will discuss and determine the feasibility of such implementation and whether to implement the same, which may include an equitable adjustment of the Product Fee in relation to the additional costs incurred by Pacira and the current and anticipated margins of Patheon. This paragraph will supersede the terms of Section 2.6 of this Agreement in relation to any inconsistency.

The following cost items are included in the Price for the Products up to the maximum facility capacity of 3M units produced:

•All costs and expenses incurred in connection with the Manufacture of Product, including costs and expenses of personnel, standard process monitoring, product / process deviations / investigations, Facility overhead, utilities, waste disposal and Supplies;

•Standard certificate of analysis (“COA”)

•Standard certificate of compliance (“COC”)

•GMP required retention samples

•Copies of deviation reports

•Batch Manufacturing Records (“BMR”) copies for all batches

•BMR changes

•Copy of the Annual Product Review Report

•Product Approval Inspection (“PAI”) and copy of FDA Report

•Simple, routine statistical review and trending of product and process data

•Storage of Production Test Record (“PTR”) batches and other experimental batches for three (3) months

•Storage of registration batches and other experimental batches for two (2) years or until Product approval, whichever comes first

•Responsibility for the sub-contract processing, by Gamma irradiation, of the filled Product vials

•Warehousing of equipment, raw materials, API and finished goods for normal commercial supply

•All routine Equipment qualification, maintenance and calibration

•Validation activities associated with equipment and product introduction, including protocols and reports

•Incoming release testing of API, excipients and associated packaging components

•Patheon standard manual visual inspection for powder products

In the event that Patheon, at any time during the Term, shall have reason to believe that it will be unable to supply Pacira with the full quantity of Product forecasted to be ordered or actually ordered by Pacira in a timely manner and in conformity with the warranty set forth in Section 6.3 (whether by reason of force majeure or otherwise), then:

(1)the terms of Section 2.7(a) will apply; and

Cost allocation for the procurement of Materials is set forth in Section 2.2 of this Agreement and Section 2.10 of the Technical Transfer Agreement.

The following shall be considered Bill Back Items:

•API Reference Standards and Analytical Reference Standards;

•High Pressure Liquid and Gas Chromatography Columns;

•Spare or replacement parts and Third Party invoices for the Maintenance of Pacira Manufacturing Equipment and Patheon Manufacturing Equipment (pursuant to Section 2.9(a)(vi)); and

•Any other minor services or small purchases necessary or required for Patheon’s performance of the Services as mutually agreed to by the Parties.

The following shall be considered Additional Services and will be invoiced to Pacira at the price given below. If no price is provided here then Patheon will provide a quotation for the activity required at the request of Pacira:

Regulatory writing activities not expressly included in the “Base Fees and Product Fees” Section above – e.g., writing CMC section, regulatory support, (other than the Reports described in Section 3.11 of this Agreement and included in the Base Fees) at £ [**]/hour; In addition, a clerical hourly billing rate of £ [**]/hour would be charged if Pacira requests the provision of additional project documentation that would not typically be provided as part of the Base Fees.

•Initial auditing of Patheon-Supplied Materials suppliers currently not on Patheon’s approved list of suppliers as further described in Schedule 1.62 (charged at £ [**] per day per auditor; the costs associated with travel, business expenses, supplier fees, etc. (if applicable) will be charged at cost).

•Complete QC testing of PLGA

•Any specific manual visual inspection of the bulk or of the finished products outside of standard manual visual inspection for powder products in accordance with the US Pharmacopeia requirements;

•Any specific shipment preparations for specific countries;

•Stability program

•Disposal of Product from engineering and non-commercial batches;

•Services resulting from a change in Applicable Law related directly to the Product or Pacira’s Manufacturing Process.

•Special projects as mutually agreed by the Parties.

Any fees for Additional Services have been agreed upon by both parties for the 2019 calendar year. The Additional Service fees will be adjusted on 1st January of each year (first review 1st January 2020) to reflect any change in UK Consumer Price Index: All Items Index published by the Office for National Statistics (as published at www.ons.gov.uk, specific details are located at http://www.ons.gov.uk/ons/rel/cpi/consumer-price-indices during the previous 12 months (based on the average of the monthly changes over the 12-month period).